Topics:

Cure is the Ultimate End-point in CRC

Cure is the Ultimate End-point in CRC

Richard M. Goldberg, MDRichard M. Goldberg, MD

In this podcast, Dr. Goldberg, Distinguished Professor, Hematology/Oncology, at the University of North Carolina Lineberger Comprehensive Cancer Center and the Physician-in-Chief of the North Carolina Cancer Hospital, spoke about the new developments in advanced colorectal cancer since his American Society if Clinical Oncology 2003 practice-changing presentation of trial data demonstrating that combination regimen FOLFOX (infusional fluorouracil [5-FU], leucovorin, and oxaliplatin [Eloxatin]) should be considered standard of care in advanced CRC. Looking forward from the meeting in 2003, to the development of targeted biologics, Dr. Goldberg said, “The lay of the land has been profoundly changed in a beneficial way due to the development of these exciting new drugs.”

Dr. Goldberg also discussed the clinical trial work that has put him at the forefront of the emerging field of pharmacogenetics, shedding light on what we have learned so far in this emerging discipline that will help guide the use of multidrug combos in the difficult clinical setting of advanced disease. He pointed out that pharmacogenetics is emerging as an important component both in facilitating new drug development and in improving the utility of existing chemotherapeutic and biologic agents.

Look for nationally regarded colorectal cancer (CRC) specialist and researcher, Dr. Richard Goldberg’s online analysis of the highlights in CRC coverage at this year’s American Society of Clinical Oncology meeting. And stay tuned for more podcasts and expert review papers from this year’s best sessions and abstracts by fellow guest editors, noted GI cancer expert Peter Enzinger, MD, Assistant Professor of Medicine, Dana-Farber Cancer Institute and leading renal cell carcinoma experts, Andrew J. Armstrong, MD ScM, Assistant Professor of Medicine and Surgery Duke Comprehensive Cancer Center, Departments of Medicine and Surgery, Divisions of Medical Oncology and Urology, and internationally regarded oncologist and clinical investigator, Robert Motzer, MD, attending physician at Memorial Sloan-Kettering Cancer Center, New York City.

—Interviewed by Ron Piana

 
Loading comments...

By clicking Accept, you agree to become a member of the UBM Medica Community.